Bristol Myers Squibb's experimental drug achieves primary endpoint in late-stage trial for lung disease.

Observed price moves

• CTNM-5.09%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.